Imidazole → (S)-2-(tert-butyldimethylsilyloxy)-1-(pyrrolidin-1-yl)propan-1-one
反応式
[OH:1][C@@H:2]([CH3:10])[C:3]([N:5]1[CH2:9][CH2:8][CH2:7][CH2:6]1)=[O:4].N1C=CN=C1.[C:16]([Si:20](Cl)([CH3:22])[CH3:21])([CH3:19])([CH3:18])[CH3:17].O>CN(C1C=CN=CC=1)C.CN(C=O)C>[Si:20]([O:1][C@@H:2]([CH3:10])[C:3]([N:5]1[CH2:9][CH2:8][CH2:7][CH2:6]1)=[O:4])([C:16]([CH3:19])([CH3:18])[CH3:17])([CH3:22])[CH3:21]参加物
7
反応物 4
生成物 1
試薬・触媒・溶媒 2
実験手順
To a solution of 108 (41.1 g, 287.0 mmol), imidazole (29.31 g, 430.6 mmol), and DMAP (3.507 g, 28.70 mmol) in DMF (100 mL) was added slowly tert-butylchlorodimethylsilane (54.08 g, 358.8 mmol) and the reaction was stirred at RT for 18 h. Water was added and mixture was extracted with Et2O. The organic layer was dried, filtered, and concentrated. The resulting residue was purified by passing through a SiO2 plug eluting with an EtOAc/hexane gradient (10 to 50% EtOAc) to afford 56.93 g (77.04%) of (S)-2-(tert-butyldimethylsilyloxy)-1-(pyrrolidin-1-yl)propan-1-one (110).
後処理
- extractionmixture was extracted with Et2O
- customThe organic layer was dried
- filtrationfiltered
- concentrationconcentrated
- customThe resulting residue was purified
- washeluting with an EtOAc/hexane gradient (10 to 50% EtOAc)
出典と根拠
- ORDレコード
- ord-2924cbacd0714900949f796d8899a9d2
- 出典データセット
- uspto-grants-2015_09
- 特許番号
- US09133187B2
反応ノート
読み込み中…